Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer

Sarah Howlett • 26 Oct 2026
ESMO 2026
Genitourinary Cancer Prostate Cancer Abiraterone
STAMPEDE

Sarah Howlett, MBBS, University College London, London, UK, presents findings on the utility of transcriptomic classifiers, specifically the Decipher score, for risk stratification in high-risk prostate cancer. Using data from the Phase III STAMPEDE trial (NCT00268476) of abiraterone in non-metastatic patients, the Decipher score identified patients in the node-negative population who derive the most benefit from abiraterone treatment escalation. These findings were further validated in a prospectively collected real-world dataset of patients who underwent Decipher scare testing as part of routine clinical care, confirming consistent prognostic utility across both trial and real-world cohorts. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026
Therapeutic strategies to induce adaptive NK cells and improve outcomes in NMIBC
1:29
Therapeutic strategies to induce adaptive NK cells and improve outcomes in NMIBC
Bérengère Salomé • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals